このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Alvotech マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Robert Wessman

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	98.3%
CEO在任期間	1.4yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Sep 03

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

May 05

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Nov 23

Alvotech starts pharmacokinetic study for its biosimilar to Amgen's bone disease drugs

Jul 20

Icelandic biosimilars developer Alvotech initiated with a hold rating by Deutsche Bank

Jul 01

CEO報酬分析

Alvotech の収益と比較して、Robert Wessman の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$494m
Dec 31 2023	US$2m	US$1m	-US$552m
Sep 30 2023	n/a	n/a	-US$596m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$713m
Dec 31 2022	US$740k	n/a	-US$514m

報酬と市場: Robertの総報酬 ($USD 1.52M ) は、 US市場 ($USD 6.80M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Robertの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Robert Wessman (54 yo)

1.4yrs

在職期間

US$1,517,000

報酬

Mr. Robert Wessman serves as Chief Executive Officer of Alvotech since January 1, 2023. He Founded Alvotech in 2013 and serves as its Executive Chairman and Member of the Board of Directors since January 2...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Wessman	CEO, Founder & Executive Chairman	1.4yrs	US$1.52m	データなし
Faysal Kalmoua	COO & Director	less than a year	データなし	0% $ 0
Joel Morales	Chief Financial Officer	4.3yrs	データなし	0.035% $ 1.3m
Giedrius Zunda	Chief Technical Officer	no data	データなし	データなし
Joseph McClellan	Chief Scientific Officer	4.7yrs	データなし	0.055% $ 2.1m
Tanya Zharov	General Counsel	1.4yrs	データなし	0% $ 0
Jenny Steingrimsdottir	Vice President of People & Culture	less than a year	データなし	データなし
Anil Okay	Chief Commercial Officer	5.9yrs	データなし	データなし
Ming Li	Chief Strategy Officer	4.4yrs	データなし	データなし
Christina Siniscalchi	Chief Quality Officer	less than a year	データなし	データなし

1.4yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: ALVOの経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Wessman	CEO, Founder & Executive Chairman	5.4yrs	US$1.52m	データなし
Faysal Kalmoua	COO & Director	4yrs	データなし	0% $ 0
Hjorleifur Palsson	Director	no data	データなし	データなし
Linda McGoldrick	Independent Non-Executive Director	2yrs	US$81.00k	0.0038% $ 144.5k
Lisa Graver	Non-Executive Director	2yrs	US$71.00k	0.0038% $ 144.5k
Tomas Ekman	Non-Executive Director	5.4yrs	データなし	データなし
Arni Hardarson	Non-Executive Director	2yrs	データなし	データなし
Richard Davies	Independent Non-Executive Deputy Chairman	5.4yrs	US$156.00k	0.37% $ 14.3m
Ann Merchant	Independent Non-Executive Director	2yrs	US$113.00k	0.0038% $ 144.5k

3.0yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: ALVOの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Alvotech マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Alvotech Appoints Hjörleifur Pálsson as Director

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Executive Changes

Alvotech Announces Changes to the Leadership Team

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Announces Executive Changes, Effective January 1, 2023

Recent updates

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Consensus revenue estimates increase by 45%

Consensus revenue estimates decrease by 41%, EPS upgraded

New major risk - Financial position

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Price target decreased by 25% to US$8.10

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Consensus revenue estimates fall by 26%

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

New minor risk - Share price stability

Consensus revenue estimates decrease by 15%, EPS upgraded

Forecast breakeven date moved forward to 2024

Price target decreased by 8.8% to US$12.40

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

Alvotech to Report Q1, 2023 Results on May 18, 2023

Consensus revenue estimates increase by 10%

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Consensus EPS estimates fall by 12%

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Less than half of directors are independent

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

マネジメント基準チェック /24